文献速递头颈PET

18F-氟脱氧葡萄糖PET与68Ga-成纤维细胞激活蛋白抑制剂PET在头颈癌中的比较:系统综述与Meta分析

Comparison of 18F-fluorodeoxyglucose PET and 68Ga-fibroblast Activation Protein Inhibitor PET in Head and Neck Cancers: A Systematic Review and Meta-analysis.
PubMed 文献 · Acad Radiol · 2025-03-10

该系统综述与Meta分析纳入12项研究共386例头颈癌患者,比较68Ga-FAPI PET与18F-FDG PET的诊断效能。68Ga-FAPI PET在基于病灶和基于患者分析中检测原发/复发肿瘤及远处转移的汇总敏感度均优于18F-FDG PET;18F-FDG PET检测淋巴结转移的敏感度更高(0.93 vs 0.82),但特异度更低(0.36 vs 0.97)。作者认为68Ga-FAPI PET在头颈癌病灶中诊断准确性更优,可能更适合用于分期和再分期。

要点

  • 68Ga-FAPI PET检测头颈癌原发/复发肿瘤及远处转移的汇总敏感度优于18F-FDG PET。
  • 淋巴结转移:18F-FDG PET敏感度0.93高于68Ga-FAPI PET的0.82,但特异度0.36低于后者的0.97。
  • 68Ga-FAPI PET远处转移汇总平均SUVmax为3.28,原发/复发肿瘤汇总平均靶本比为1.24,均高于18F-FDG PET。

核心结论

  • 与18F-FDG PET相比,68Ga-FAPI PET在头颈癌病灶中具有更优的诊断准确性,可能更适合用于头颈癌患者的分期和再分期。

研究设计与样本

  • 系统综述与Meta分析,检索PubMed、Embase、Web of Science和Cochrane Library截至2024年6月26日,纳入12项比较68Ga-FAPI PET与18F-FDG PET诊断价值的研究,共386例头颈癌患者,采用双变量诊断数据Meta分析和定量参数Meta分析,绘制汇总受试者工作特征曲线,并用Egger检验评估发表偏倚。

诊断标准与关键数值

  • 淋巴结转移检测:18F-FDG PET敏感度0.93(95%CI 0.83-0.97)高于68Ga-FAPI PET的0.82(95%CI 0.63-0.93),特异度0.36(95%CI 0.01-0.96)低于68Ga-FAPI PET的0.97(95%CI 0.53-1.00)。
  • 远处转移定量参数:68Ga-FAPI PET汇总平均SUVmax为3.28(95%CI 1.90-4.66),高于18F-FDG PET。
  • 原发/复发肿瘤定量参数:68Ga-FAPI PET汇总平均靶本比为1.24(95%CI 0.44-2.04),高于18F-FDG PET。

临床应用与阅片要点

  • 在基于病灶和基于患者的分析中,68Ga-FAPI PET检测原发/复发肿瘤及远处转移的汇总敏感度均优于18F-FDG PET。
  • 评估淋巴结转移时,18F-FDG PET敏感度更高但特异度更低,68Ga-FAPI PET特异度更高但敏感度较低。
  • 作者认为68Ga-FAPI PET可能比18F-FDG PET更适合用于头颈癌患者的分期和再分期。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: This study aimed to compare the diagnostic efficiency of 68Ga-fibroblast activation protein inhibitor (FAPI) positron emission tomography (PET) and 18F-fluorodeoxyglucose (18F-FDG) PET in patients with head and neck cancer (HNC).

DATA SOURCES: PubMed, Embase, Web of Science, and the Cochrane Library were used to perform a systemic search through June 26, 2024.

METHODS: Studies comparing the diagnostic value of 68Ga-FAPI PET and 18F-FDG PET in patients with HNC were included. We performed a bivariate meta-analysis of diagnostic data and a meta-analysis of the quantitative parameters. The summary receiver operating characteristic curve was plotted, and publication bias was evaluated via Egger's test.

RESULTS: The meta-analysis included 12 studies on 386 patients with HNC. 68Ga-FAPI PET had superior pooled sensitivity to 18F-FDG PET in detecting primary/recurrent tumors and distant metastases in both lesion-based analysis and patient-based analysis. Although the sensitivity of 18F-FDG PET for detecting lymph node metastases was greater than that of 68Ga-FAPI PET (0.93 [95% CI 0.83-0.97] vs. 0.82 [95% CI 0.63-0.93]), the specificity of 18F-FDG PET was lower than that of 68Ga-FAPI PET (0.36 [95% CI 0.01-0.96] vs. 0.97 [95% CI 0.53-1.00]). In addition, 68Ga-FAPI PET had a higher pooled mean maximum standardized uptake value for distant metastases (3.28 [95% CI 1.90-4.66]) and a higher pooled mean tumor-to-background ratio for primary/recurrent tumors (1.24 [95% CI 0.44-2.04]) than 18F-FDG PET.

CONCLUSION: Compared to 18F-FDG PET, 68Ga-FAPI PET has superior diagnostic accuracy in HNC lesions. Thus, 68Ga-FAPI PET may be a better tool for staging and restaging than 18F-FDG PET in patients with HNC.

来源:Acad Radiol,查看原文。版权归原作者所有。

引用

  1. Huang S, Wang Y, Huang R, et al. Comparison of 18F-fluorodeoxyglucose PET and 68Ga-fibroblast Activation Protein Inhibitor PET in Head and Neck Cancers: A Systematic Review and Meta-analysis. Acad Radiol. 2025. PMID: 40068998. doi:10.1016/j.acra.2025.02.038

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。